Released Oct 6, 2025, after the close
10-Q filed Nov 13, 2025, 44 days after period end · 0001104659-25-111378
Q3 2025 · 10-Q
Revenue$5.06M$5.06M +99.0% vs Q3 2024+155.4% vs Q2 2025
Net Income-$7.98M-$7.98M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.26-$0.26 N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$3,931,000+119.9%
Operating Income-$8,913,000N/M
Operating Cash Flowderived-$9,614,000N/M
Margins · derived
Gross margin77.7%+7.4 pt vs Q3 2024
Operating margin-176.2%+177.8 pt vs Q3 2024
Net margin-157.7%+210.7 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 |
|---|---|---|
| Revenue | $5.06M | $2.54M |
| Net Income | -$7.98M | -$9.37M |
| EPS Diluted | -$0.26 | $0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR